

# Abidi Diabetes Portfolio

 **Gloripa**<sup>®</sup>  
Empagliflozin

 **Synoripa**<sup>®</sup>  
Empagliflozin / Metformin

 **Glorenta**<sup>®</sup>  
Empagliflozin / Linagliptin

**Ziptin**<sup>®</sup>  
Sitagliptin

**Zipmet**<sup>®</sup>  
Sitagliptin / Metformin

 **Lirenta**<sup>®</sup>  
Linagliptin

 **Liroprim**<sup>®</sup>  
Linagliptin / Metformin

 **Gloripa**<sup>®</sup>  
Empagliflozin

 **Synoripa**<sup>®</sup>  
Empagliflozin / Metformin



Get to the  
**HEART** of Diabetes

# Gloripa<sup>®</sup>

## Dosage & Administration<sup>1</sup>



The recommended dose of Gloripa<sup>®</sup> is 10 mg once daily, taken in the morning, with or without food



Dose may be increased to 25 mg once daily




Assess renal function before initiating Gloripa<sup>®</sup>



Do not initiate Gloripa<sup>®</sup> if eGFR\* is below 45 mL/min/1.73 m<sup>2</sup>



Discontinue Gloripa<sup>®</sup> if eGFR\* is below 45 mL/min/1.73 m<sup>2</sup>



Gloripa<sup>®</sup> is contraindicated in patients with an eGFR\* less than 30 mL/min/1.73 m<sup>2</sup>



# Synoripa®

## Dosage & Administration<sup>2</sup>



Individualize the starting dose of Synoripa® based on the patient's current regimen



The maximum recommended dose is 12.5 mg empagliflozin/1000 mg metformin hydrochloride twice daily



Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin



Assess renal function before initiating



Synoripa® is contraindicated in patients with an eGFR\* below 45 mL/min/1.73 m<sup>2</sup>



 **Glorenta**<sup>®</sup>  
Empagliflozin / Linagliptin



**All Paths Lead to  NE**

**Glorenta<sup>®</sup>**

## Dosage & Administration<sup>3</sup>

- The recommended dose of Glorenta<sup>®</sup> is 10mg empagliflozin/5 mg linagliptin once daily, taken in the morning, with or without food
- Dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily
- Assess renal function before initiating Glorenta<sup>®</sup>
- Do not initiate Glorenta<sup>®</sup> if eGFR\* is below 45 mL/min/1.73 m<sup>2</sup>
- Discontinue Glorenta<sup>®</sup> if eGFR\* falls persistently below 45 mL/min/1.73 m<sup>2</sup>
- Glorenta<sup>®</sup> is contraindicated in patients with an eGFR\* less than 30 mL/min/1.73 m<sup>2</sup>



**Ziptin**<sup>®</sup>  
Sitagliptin

**Zipmet**<sup>®</sup>  
Sitagliptin / Metformin



**Safe Journey to  
a Better Balance**



# Ziptin® / Zipmet®

## Ziptin® Dosage & Administration<sup>4</sup>

<b>Adult Patients with Type 2 DM</b>		<b>100 mg Once Daily</b>
<b>Dosage Adjustment in Renal Impairment</b>		
<b>Mild Renal Insufficiency</b>	GFR ≥ 45 ml/min	100 mg Once Daily
<b>Moderate Renal Insufficiency</b>	30 ≤ GFR < 45 ml/min	50 mg Once Daily
<b>Severe Renal Insufficiency and ESRD</b>	GFR < 30 ml/min	25 mg Once Daily

Available in 25, 50 & 100 mg film coated tablets



## Zipmet® Dosage & Administration<sup>5</sup>

<p>In patients not currently treated with metformin</p> <p>↓</p> <p><b>Zipmet® 50/500 mg twice daily with gradual dose escalation</b></p>	<p>In patients already treated with metformin</p> <p>↓</p> <p><b>Sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken</b></p>	<p>In patients on maximum metformin-based therapy</p> <p>↓</p> <p><b>Zipmet® 50/1000mg twice daily</b></p>
---	---	--





One Dose Fits All

**Lirenta<sup>®</sup>**

## Dosage & Administration<sup>6</sup>

- The recommended dose of Lirenta<sup>®</sup> is 5 mg once daily
- Lirenta<sup>®</sup> can be taken with or without food
- No dose adjustment based on renal function



# Liroprim<sup>®</sup>

Linagliptin/Metformin



It should be  
**LESS**

# Liroprim®

## Dosage & Administration<sup>7</sup>

- The maximum recommended dose of Liroprim® is 2.5 mg linagliptin/1000 mg metformin HCl twice daily with meals
- Assess renal function before initiating of Liroprim®
- Do not use Liroprim® in patients with eGFR\* below 30 mL/min/1.73 m<sup>2</sup>
- Initiation of Liroprim® is not recommended in patients with eGFR\* between 30-45 mL/min/1.73 m<sup>2</sup>
- Assess risk/benefit of continuing if eGFR\* falls below 45 mL/min/1.73 m<sup>2</sup>
- Discontinue if eGFR\* falls below 30 mL/min/1.73 m<sup>2</sup>
- Liroprim® may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures



\*eGFR: estimated Glomerular Filtration Rate

#### References:

- 1- Empagliflozin FDA Label 2020; ID: 4551023.
- 2- Empagliflozin and Metformin FDA Label 2020; ID: 4551023.
- 3- Empagliflozin and Linagliptin FDA Label 2020; ID: 4583067.
- 4- Sitagliptin FDA Label 2019; ID: 4475738.
- 5- Sitagliptin and Metformin FDA Label 2019; ID: 4475738.
- 6- Linagliptin FDA Label 2020; ID: 4583067.
- 7- Linagliptin and Metformin FDA Label 2020; ID: 4583067.